Bristol Myers Squib agreed to buy Karuna Therapeutics for $14 billion on Friday, gaining a promising experimental schizophrenia drug.

Was this article helpful?
YesNo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window